Institutional members access full text with Ovid®

Share this article on:

INTRAOCULAR PRESSURE CHANGES AFTER DEXAMETHASONE IMPLANT IN PATIENTS WITH GLAUCOMA AND STEROID RESPONDERS

Srinivasan, Rekha, MPhil Optometry*,†; Sharma, Unnati, MS*; George, Ronnie, MS, DNB; Raman, Rajiv, MS*; Sharma, Tarun, MD* for the Sankara Nethralaya Vitreoretinal Study Group (SNVR Study Group)

doi: 10.1097/IAE.0000000000001924
Original Study: PDF Only

Purpose: To assess the changes in intraocular pressure (IOP) after dexamethasone (DEX) implant in patients with glaucoma or history of steroid responders.

Methods: A retrospective study of patients who received DEX implant was conducted in a tertiary care center in India. Demographic details and IOP measurements at preinjection and postinjection were collected. The proportion of patients with and without IOP rise after DEX implant was noted, and the number of antiglaucoma medications to control the IOP was analyzed. The changes in IOP were also compared in the group with no glaucoma/steroid responder.

Results: A total of 815 patients, 767 patients in the nonglaucoma group and 48 patients in the glaucoma referral group, who underwent DEX implant were included in this study. The overall mean (SD) age of study participants was 56.3 (SD = 12.6) years. The overall mean (SD) IOP at baseline and at follow-up after injection for both nonglaucoma and glaucoma referral groups was found to be significant (P < 0.001). The differences in IOP measurements across follow-ups after DEX implant were found to be significant in both nonglaucoma (P < 0.001) and glaucoma referral groups (P < 0.001). Among the study patients in the IOP-rise group, 46.43% had maximum IOP rise in 1-week follow-up and 39% in 2-week follow-up, where 78.6% showed IOP controlled with 1 antiglaucoma medication.

Conclusion: The rise in IOP after DEX implant was noted within first 2 weeks, which can be managed with topical antiglaucoma medications. Hence, with a close early follow-up monitoring of IOP, and timely medical intervention, DEX implant can be performed in patients with glaucoma.

A retrospective study to assess the effects of dexamethasone intravitreal implant on intraocular pressure in a cohort of patients with glaucoma or steroid responders from a real-life clinical practice.

*Shri Bhagwan Mahavir Vitreoretinal Services, Sankara Nethralaya, Chennai, India; and

Department of Glaucoma, Medical Research Foundation, Sankara Nethralaya, Chennai, India.

Reprint requests: Rajiv Raman, MS, DNB, Shri Bhagwan Mahavir Vitreoretinal Services, 18 College Road, Sankara Nethralaya, Chennai 600 006, Tamil Nadu, India; e-mail: rajivpgraman@gmail.com

None of the authors has any financial/conflicting interests to disclose.

A full listing of the Sankara Nethralaya Vitreoretinal Study Group (SNVR-Study Group) is available online in the Appendix at www.aaojournal.org.

© 2018 by Ophthalmic Communications Society, Inc.